Clinical trials: Colorectal Carcinoma (CRC)
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Colorectal Neoplasms Malignant, Colonoscopy
Sensitivity of Fecal Immunochemical Test (FIT) for Colorectal Cancer (CRC) Screening
Fecal immunochemical test (FIT) was introduced in France late 2015, FIT has better diagnostic accuracy for colorectal cancers (CRCs) than previous screening tests.
- Conditions
- Colorectal Neoplasms Malignant, Colonoscopy, Early Detection of Cancer, Female
- Trial name
- FITBACK (NCT05163236)
- Testing
- Positive fecal immunochemical test (FIT), Negative fecal immunochemical test (FIT), Fecal immunochemical test (FIT) not performed
- Where
- France
- Volunteers
- 1,149 people
- Sponsor
- University Hospital, Brest
Metastatic Colorectal Cancer (CRC), Colorectal Cancer
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with chemotherapy.
- Trial name
- NCT07286695
- Testing
- Fruquintinib Combined With trifluridine/tipiracil, Bevacizumab combined with trifluridine/tipiracil
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy
The purpose of this study is to assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with…
- Trial name
- NCT02597075
- Testing
- standard therapy + physical activity program, standard therapy
- Where
- 24 sites in Austria, Switzerland
- Volunteers
- 100 people
- Sponsor
- Swiss Cancer Institute
Metastatic Colorectal Cancer
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.
- Trial name
- OPTIPRIME (NCT03584711)
- Testing
- FOLFOX + panitumumab
- Where
- 124 sites in France, Martinique
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer (mCRC)
Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)
The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.
- Trial name
- REACH (NCT06938971)
- Testing
- Exercise training
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Colorectal Cancer
A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy
Objective: To assess the effect of bevacizumab on tumor vessels, and the reversibility of the effect, using contrast-enhanced ultrasonography (CEUS) and histology in patients with metastatic liver tumors derived from colorectal…
- Trial name
- NCT01591109
- Volunteers
- 20 people
- Sponsor
- NHO - Matsumoto Medical Center
Colorectal Cancer
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with…
- Trial name
- NCT03146377
- Testing
- Capecitabine, Oxaliplatin, Irinotecan
- Where
- Hong Kong
- Volunteers
- 32 people
- Sponsor
- The University of Hong Kong
Metastatic Colorectal Cancer
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
To explore the safety, efficacy and pharmacokinetic (PK) characteristics of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: a…
- Trial name
- NCT05775900
- Testing
- Cetuximab, Capecitabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Colorectal Tumor
Comparison of Diagnostic Sensitivity Between ctDNA Methylation and CEA in Colorectal Cancer
This is a prospective diagnostic study. This study is to compare the performance between circulating tumor DNA (ctDNA) methylation and carcinoembryonic antigen (CEA) in detecting colorectal tumor.
- Trial name
- NCT05558436
- Testing
- Genome-wide methylation profiling
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer
A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)
Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic…
- Trial name
- FRESCO (NCT02314819)
- Testing
- fruquintinib
- Where
- 15 sites in China
- Volunteers
- 416 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Cancer, Colorectal Carcinoma
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing
- Trial name
- MORA (NCT02273167)
- Testing
- NER1006, 2-Day Split-Dosing, NER1006,1-Day Morning Split-Dosing, MOVIPREP, 2-Day Split-Dosing
- Where
- 29 sites in Belgium, France and 5 more
- Volunteers
- 849 people
- Sponsor
- Norgine
Colonic Cancer
Aquamin and Prevention of Colon Cancer
In the proposed study, investigators will conduct a 90-day dietary intervention study in human subjects. Thirty individuals at risk for adenomatous colon polyp formation will be randomized to receive a calcium and…
- Trial name
- NCT02647671
- Testing
- Aquamin®, Calcium Carbonate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- James Varani
Metastatic Colorectal Cancer, KRAS Gene Mutation
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.
- Trial name
- NCT04446793
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Sponsor
- Cardiff Oncology
Metastatic Colorectal Cancer
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
The purpose of this study is to assess the objective response rate (ORR) when panitumumab is administered in combination with irinotecan as 2nd-line therapy in subjects with previously treated metastatic colorectal cancer (mCRC).
- Trial name
- NCT00475293
- Testing
- Panitumumab and CPT-11
- Where
- Spain
- Volunteers
- 85 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Locally Advanced Colorectal Cancer
Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
This is an exploratory study to evaluate the efficacy and safety of neoadjuvant therapy with serplulimab combined with CAPOX and bevacizumab for patients with locally advanced colorectal cancer.
- Trial name
- NCT07819604
- Testing
- Serplulimab, CAPOX, Bevacizumab
- Volunteers
- 85 people
- Sponsor
- Xijing Hospital
Colorectal Cancer, Microsatellite Instability High
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) for dMMR/MSI-H colorectal cancer staged as locally advanced (cT3-4N+/-M0…
- Trial name
- NCT04715633
- Testing
- PD-1 inhibitor plus VEGF inhibitors
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic, Liver Metastases
Irinotecan Drug-eluting Bead Liver Embolisation Registry
Purpose: The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery…
- Trial name
- DLivERDEBIRI (NCT03697044)
- Testing
- Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Colorectal Cancer
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
This is a multi-center Phase II randomized study. We plan to enroll 78 patients with biopsy-proven hepatic-limited metastatic colorectal cancer deemed resectable after multi-disciplinary discussion.
- Trial name
- NCT03547999
- Testing
- mFOLFOX6, MVA-BN-CV301, FPV-CV301
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Patrick Boland
Advanced Malignancies, Oncology
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
- Conditions
- Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT07504263
- Testing
- RP-001
- Volunteers
- 66 people
- Sponsor
- Recurv Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.